We have qualitatively reviewed this strategy and reaffirmed its Process and People ratings. Vanguard Capital Opportunity stands out for its seasoned management and high-conviction multimanager system. The remainder of this analysis is from July 7, 2023.
Vanguard Capital Opportunity Adm VHCAX
- NAV / 1-Day Return 203.38 / +0.15 %
- Total Assets 22.4 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.360%
- Distribution Fee Level Low
- Share Class Type Institutional
- Category Large Growth
- Investment Style Large Growth
- Min. Initial Investment 50,000
- Status Limited
- TTM Yield 0.67%
- Turnover 6%
USD | NAV as of Jul 05, 2024 | 1-Day Return as of Jul 05, 2024, 10:26 PM GMT+0
Morningstar’s Analysis VHCAX
Will VHCAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 31.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 11.36 | 2.6 Bil | Healthcare |
Mktliq 12/31/2049 | 4.66 | 1.1 Bil | Cash and Equivalents |
Amgen Inc | 2.67 | 603.8 Mil | Healthcare |
Micron Technology Inc | 2.62 | 591.6 Mil | Technology |
Microsoft Corp | 2.56 | 579.0 Mil | Technology |
KLA Corp | 2.32 | 523.4 Mil | Technology |
Biogen Inc | 2.14 | 483.7 Mil | Healthcare |
FedEx Corp | 2.11 | 477.9 Mil | Industrials |
Biomarin Pharmaceutical Inc | 2.09 | 472.3 Mil | Healthcare |
Flex Ltd | 1.90 | 430.3 Mil | Technology |